Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer's Disease at the Alzheimer's Association International Conference® (AAIC)

By Yahoo! Finance | Jul 28, 2024 at 04:51 PM EST

Longeveron Inc. presents promising Phase 2a clinical trial data on Lomecel-B™ at the AAIC 2024, showing improvements in cognitive function and brain volume in mild Alzheimer's Disease. The therapy demonstrated safety and efficacy, supporting its potential as a novel treatment.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.